X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-09-17 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $6.84 | -11,447 | 7,109,875 | 0% | -$78,333 | ||||||
| D | 2024-09-18 | PCVX | Vaxcyte, Inc. | Guggenhime Andrew | Pres, CFO | S - Sale+OE | $115.94 | -8,000 | 90,383 | -8% | -$927,551 | |||||
| M | 2024-09-17 | NMRA | Neumora Therapeutics, Inc. | Lenz Robert A. | Head of R, D | S - Sale | $11.89 | -41,464 | 328,529 | -11% | -$492,827 | |||||
2024-09-16 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $8.58 | -1,936 | 142,768 | -1% | -$16,611 | ||||||
| DM | 2024-09-17 | HALO | Halozyme Therapeutics, Inc. | Labarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | S - Sale+OE | $62.45 | -20,000 | 173,756 | -10% | -$1,249,096 | |||||
| M | 2024-09-16 | PASG | Passage Bio, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $0.73 | -200,131 | 7,833,869 | -2% | -$146,727 | |||||
| D | 2024-09-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $16.33 | -500 | 6,781 | -7% | -$8,165 | |||||
| D | 2024-09-17 | PCVX | Vaxcyte, Inc. | Loxam Teri | Dir | S - Sale+OE | $116.28 | -6,250 | 7,175 | -47% | -$726,731 | |||||
| D | 2024-09-16 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale+OE | $115.96 | -10,000 | 200,646 | -5% | -$1,159,635 | |||||
2024-09-16 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale | $44.19 | -2,244 | 98,932 | -2% | -$99,152 | ||||||
2024-09-16 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $44.19 | -11,715 | 816,622 | -1% | -$517,631 | ||||||
2024-09-16 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale | $44.19 | -4,331 | 132,320 | -3% | -$191,367 | ||||||
2024-09-16 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $44.19 | -4,665 | 264,408 | -2% | -$206,124 | ||||||
2024-09-16 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $44.19 | -1,454 | 45,634 | -3% | -$64,245 | ||||||
2024-09-16 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $46.42 | -94 | 78,627 | 0% | -$4,364 | ||||||
| D | 2024-09-17 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale+OE | $77.73 | -15,000 | 6,915 | -68% | -$1,165,880 | |||||
| D | 2024-09-17 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $48.28 | -13,500 | 0 | -100% | -$651,766 | |||||
2024-09-13 | NBIX | Neurocrine Biosciences Inc | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $121.88 | -3,461 | 1,672 | -67% | -$421,828 | ||||||
2024-09-16 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.30 | +5,000 | 1,493,042 | 0% | +$1,515 | ||||||
| D | 2024-09-12 | INMB | Inmune Bio, Inc. | Tesi Raymond Joseph | Pres, CEO, 10% | P - Purchase | $6.38 | +15,380 | 1,554,106 | +1% | +$98,048 | |||||
| D | 2024-09-12 | INMB | Inmune Bio, Inc. | Moss David J | CFO, 10% | P - Purchase | $6.38 | +7,690 | 1,275,869 | +1% | +$49,024 | |||||
| M | 2024-09-12 | INBX | Inhibrx Biosciences, Inc. | Lappe Mark | CEO | P - Purchase | $15.73 | +40,000 | 925,413 | +5% | +$629,117 | |||||
2024-09-12 | CHRO | Chromocell Therapeutics Corp | Malamut Richard | Dir | P - Purchase | $0.94 | +10,400 | 91,565 | +13% | +$9,825 | ||||||
| M | 2024-09-12 | CHRO | Chromocell Therapeutics Corp | Francis Knuettel II | CEO, Pres, CFO, Treas, Secty | P - Purchase | $0.97 | +5,200 | 547,710 | +1% | +$5,044 | |||||
| D | 2024-09-12 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $6.17 | -316 | 5,609 | -5% | -$1,950 | |||||
| D | 2024-09-12 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $6.17 | -1,148 | 28,749 | -4% | -$7,085 | |||||
2024-09-12 | IPSC | Century Therapeutics, Inc. | Quimi Daphne | Dir | P - Purchase | $1.53 | +5,000 | 5,000 | New | +$7,657 | ||||||
2024-09-13 | DNLI | Denali Therapeutics Inc. | Sato Vicki L | Dir | S - Sale | $30.00 | -1,020 | 115,156 | -1% | -$30,600 | ||||||
2024-09-12 | NMRA | Neumora Therapeutics, Inc. | Lenz Robert A. | Head of R, D | S - Sale | $11.43 | -32,948 | 369,993 | -8% | -$376,665 | ||||||
| D | 2024-09-13 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $43.32 | -16,667 | 269,073 | -6% | -$722,087 | |||||
2024-09-13 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.31 | +20,000 | 1,488,042 | +1% | +$6,160 | ||||||
| D | 2024-09-12 | GILD | Gilead Sciences, Inc. | Parsey Merdad | Chief Medical Officer | S - Sale+OE | $84.50 | -21,246 | 102,189 | -17% | -$1,795,287 | |||||
| M | 2024-09-11 | GLUE | Monte Rosa Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $6.00 | -567,213 | 8,329,840 | -6% | -$3,404,791 | |||||
2024-09-11 | CDTX | Cidara Therapeutics, Inc. | Sandison Taylor | Chief Medical Officer | S - Sale | $11.64 | -924 | 23,067 | -4% | -$10,752 | ||||||
2024-09-11 | CDTX | Cidara Therapeutics, Inc. | Tari Leslie | CHIEF SCIENTIFIC OFFICER | S - Sale | $11.64 | -909 | 17,861 | -5% | -$10,580 | ||||||
2024-09-12 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Pres, R, D, 10% | S - Sale | $197.77 | -50,000 | 3,203,144 | -2% | -$9,888,276 | ||||||
2024-09-12 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Pres, CEO, 10% | S - Sale | $197.77 | -50,000 | 3,203,144 | -2% | -$9,888,276 | ||||||
2024-09-12 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale | $83.78 | -29,357 | 78,127 | -27% | -$2,459,577 | ||||||
2024-09-11 | ZURA | Zura Bio Ltd | Thiara Parvinder | Dir | S - Sale | $2.70 | -3,800,000 | 1,001,633 | -79% | -$10,260,000 | ||||||
| DM | 2024-09-11 | VCEL | Vericel Corp | Colangelo Dominick | Pres, CEO | S - Sale+OE | $43.64 | -35,000 | 220,937 | -14% | -$1,527,225 | |||||
| M | 2024-09-11 | TARA | Protara Therapeutics, Inc. | Opaleye Management Inc. | 10% | S - Sale | $1.71 | -158,901 | 1,989,134 | -7% | -$271,715 | |||||
| DM | 2024-09-10 | RXRX | Recursion Pharmaceuticals, Inc. | Secora Michael | CFO | S - Sale+OE | $6.24 | -30,000 | 1,402,131 | -2% | -$187,229 | |||||
| D | 2024-09-10 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $74.41 | -1,500 | 0 | -100% | -$111,615 | |||||
| DM | 2024-09-10 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $59.13 | -30,000 | 676,744 | -4% | -$1,773,790 | |||||
| M | 2024-09-10 | CHRO | Chromocell Therapeutics Corp | Francis Knuettel II | CEO, Pres, CFO, Treas, Secty | P - Purchase | $0.91 | +12,000 | 542,510 | +2% | +$10,955 | |||||
| D | 2024-09-12 | JSPR | Jasper Therapeutics, Inc. | Mahal Jeetinder Singh | COO | S - Sale+OE | $21.23 | -900 | 25,009 | -3% | -$19,104 | |||||
| M | 2024-09-10 | INBX | Inhibrx Biosciences, Inc. | Vuori Kristiina Md | Dir | P - Purchase | $15.07 | +6,636 | 13,776 | +93% | +$99,992 | |||||
| D | 2024-09-10 | RGEN | Repligen Corp | Hunt Anthony | Dir | S - Sale+OE | $145.37 | -22,191 | 139,840 | -14% | -$3,225,927 | |||||
| D | 2024-09-09 | ADMA | Adma Biologics, Inc. | Guiheen Lawrence P. | Dir | S - Sale+OE | $18.47 | -9,000 | 154,941 | -5% | -$166,189 | |||||
| D | 2024-09-10 | HUMA | Humacyte, Inc. | Sebelius Kathleen | Dir | S - Sale+OE | $5.40 | -5,182 | 41,207 | -11% | -$28,004 | |||||
| M | 2024-09-09 | HUMA | Humacyte, Inc. | Dougan Brady W | Dir | S - Sale | $5.30 | -446,378 | 5,131,339 | -8% | -$2,364,521 | |||||
| M | 2024-09-09 | HUMA | Humacyte, Inc. | Niklason Laura E | Pres, CEO, Dir | S - Sale | $5.30 | -446,378 | 5,131,339 | -8% | -$2,364,521 | |||||
| D | 2024-09-10 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale+OE | $10.65 | -5,000 | 120,695 | -4% | -$53,274 | |||||
2024-09-09 | XFOR | X4 Pharmaceuticals, Inc | Dibiase Mary | COO | S - Sale | $0.66 | -2,642 | 289,110 | -1% | -$1,738 | ||||||
| M | 2024-09-09 | TARA | Protara Therapeutics, Inc. | Opaleye Management Inc. | 10% | S - Sale | $1.84 | -61,992 | 2,148,035 | -3% | -$114,251 | |||||
| M | 2024-09-06 | INBX | Inhibrx Biosciences, Inc. | Lappe Mark | CEO | P - Purchase | $15.25 | +44,000 | 885,413 | +5% | +$671,150 | |||||
2024-09-09 | VIR | Vir Biotechnology, Inc. | Napolitano Janet | Dir | S - Sale | $7.80 | -12,190 | 11,616 | -51% | -$95,032 | ||||||
| D | 2024-09-09 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | GC | S - Sale+OE | $73.57 | -551 | 18,154 | -3% | -$40,539 | |||||
2024-09-06 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $39.16 | -275 | 78,721 | 0% | -$10,769 | ||||||
2024-09-06 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $39.16 | -912 | 88,192 | -1% | -$35,715 | ||||||
2024-09-06 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $39.16 | -240 | 38,724 | -1% | -$9,399 | ||||||
| D | 2024-09-06 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $39.16 | -2,340 | 497,253 | 0% | -$91,637 | |||||
2024-09-05 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $18.09 | -8,000 | 115,942 | -6% | -$144,720 | ||||||
2024-09-04 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $47.56 | -6,665 | 280,793 | -2% | -$316,969 | ||||||
2024-09-04 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $47.62 | -40,000 | 1,394,487 | -3% | -$1,904,841 | ||||||
| D | 2024-09-05 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale+OE | $70.02 | -3,421 | 9,278 | -27% | -$239,526 | |||||
2024-09-04 | ZURA | Zura Bio Ltd | Sidhu Someit | Dir | S - Sale | $3.87 | -51,728 | 3,623,319 | -1% | -$200,187 | ||||||
2024-09-05 | MGX | Metagenomi, Inc. | Wapnick Pamela | CFO | S - Sale | $2.88 | -6,265 | 63,051 | -9% | -$18,043 | ||||||
| DM | 2024-09-04 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $6.09 | -40,000 | 762,656 | -5% | -$243,600 | |||||
2024-09-04 | EDIT | Editas Medicine, Inc. | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | S - Sale | $3.42 | -518 | 133,895 | 0% | -$1,774 | ||||||
2024-09-04 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | CEO | S - Sale | $3.42 | -1,555 | 313,724 | 0% | -$5,325 | ||||||
2024-09-05 | ATHA | Athira Pharma, Inc. | Gengos Andrew | CFO, CHIEF BUSINESS OFFICER | S - Sale | $0.57 | -1,272 | 97,532 | -1% | -$720 | ||||||
2024-09-05 | ATHA | Athira Pharma, Inc. | Lenington Rachel | COO, CDO | S - Sale | $0.57 | -2,525 | 20,870 | -11% | -$1,429 | ||||||
2024-09-05 | ATHA | Athira Pharma, Inc. | Church Kevin | Chief Scientific Officer | S - Sale | $0.57 | -2,525 | 92,684 | -3% | -$1,429 | ||||||
2024-09-05 | ATHA | Athira Pharma, Inc. | Worthington Mark | GC | S - Sale | $0.57 | -2,525 | 51,927 | -5% | -$1,429 | ||||||
2024-09-05 | ATHA | Athira Pharma, Inc. | Litton Mark James | Pres, CEO | S - Sale | $0.57 | -5,032 | 179,054 | -3% | -$2,848 | ||||||
2024-09-03 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $6.27 | -11,447 | 7,121,322 | 0% | -$71,718 | ||||||
| D | 2024-09-03 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale+OE | $111.93 | -10,000 | 201,958 | -5% | -$1,119,252 | |||||
| D | 2024-09-03 | PCVX | Vaxcyte, Inc. | Cowan Elvia | SVP, Finance | S - Sale+OE | $107.67 | -5,000 | 11,578 | -30% | -$538,350 | |||||
| D | 2024-09-03 | PCVX | Vaxcyte, Inc. | Eydelman Mikhail | SVP, GC, Corp Sec | S - Sale+OE | $112.11 | -1,667 | 28,623 | -6% | -$186,880 | |||||
| D | 2024-09-04 | VCEL | Vericel Corp | Gilman Steven C | Dir | S - Sale+OE | $48.58 | -5,000 | 11,000 | -31% | -$242,900 | |||||
| D | 2024-09-03 | VCEL | Vericel Corp | Hopper Jonathan Mark | Chief Medical Officer | S - Sale+OE | $49.83 | -10,000 | 58,229 | -15% | -$498,300 | |||||
| D | 2024-09-03 | BIIB | Biogen Inc. | Singhal Priya | Head of Development | S - Sale+OE | $204.22 | -431 | 5,316 | -7% | -$88,019 | |||||
| D | 2024-09-03 | RGNX | Regenxbio Inc. | Karabelas Argeris N | Dir | S - Sale+OE | $11.56 | -10,000 | 11,286 | -47% | -$115,588 | |||||
2024-09-04 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $5.52 | -2,431 | 66,432 | -4% | -$13,419 | ||||||
2024-09-03 | DNLI | Denali Therapeutics Inc. | Sato Vicki L | Dir | S - Sale | $25.00 | -3,080 | 116,176 | -3% | -$77,007 | ||||||
| D | 2024-09-03 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | GC | S - Sale+OE | $76.99 | -114 | 17,566 | -1% | -$8,777 | |||||
2024-09-03 | ALEC | Alector, Inc. | Grasso Marc | CFO | S - Sale | $4.88 | -7,297 | 130,740 | -5% | -$35,620 | ||||||
| D | 2024-09-03 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $76.99 | -318 | 1,599,051 | 0% | -$24,483 | |||||
2024-09-03 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $4.88 | -26,499 | 5,879,121 | 0% | -$129,387 | ||||||
2024-09-03 | ALEC | Alector, Inc. | Kenkare-Mitra Sara | Pres, Head of R, D | S - Sale | $4.88 | -13,926 | 291,715 | -5% | -$67,981 | ||||||
2024-09-03 | ALEC | Alector, Inc. | Romano Gary | Chief Medical Officer | S - Sale | $4.88 | -8,478 | 179,795 | -5% | -$41,385 | ||||||
2024-09-03 | SWTX | Springworks Therapeutics, Inc. | Islam Saqib | CEO | S - Sale | $40.57 | -49,000 | 1,063,368 | -4% | -$1,988,033 | ||||||
2024-09-03 | SWTX | Springworks Therapeutics, Inc. | Edris Badreddin | COO | S - Sale | $40.65 | -20,000 | 229,600 | -8% | -$812,954 | ||||||
| D | 2024-09-03 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale+OE | $67.03 | -27,451 | 9,278 | -75% | -$1,840,053 | |||||
| M | 2024-08-30 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | 10% | P - Purchase | $2.20 | +10,000 | 268,604 | +4% | +$22,000 | |||||
| M | 2024-08-29 | QNCX | Quince Therapeutics, Inc. | Thye Dirk | CEO, CHIEF MEDICAL OFFICER | P - Purchase | $0.69 | +154,500 | 843,941 | +22% | +$107,375 | |||||
| M | 2024-08-29 | INBX | Inhibrx Biosciences, Inc. | Lappe Mark | CEO | P - Purchase | $14.92 | +40,000 | 841,413 | +5% | +$596,763 | |||||
| D | 2024-08-29 | RXRX | Recursion Pharmaceuticals, Inc. | Marriott Tina | Pres, COO | S - Sale+OE | $7.56 | -6,000 | 521,138 | -1% | -$45,376 | |||||
2024-08-29 | INBX | Inhibrx Biosciences, Inc. | Vuori Kristiina Md | Dir | P - Purchase | $14.00 | +7,140 | 7,140 | New | +$99,960 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |